SA 16a - Rectal cancer: where do we stand and where do we go?
March 6, 16:00 - 17:30 CET
3 min
Chairperson's introduction
18 min
Where do we stand? Primary rectal cancer staging
To discuss the role of imaging in early rectal cancers.
To learn about sphincter complex anatomy in relation to low rectal cancers.
To become familiar with extra TNM prognostic imaging markers such as EMVI and mesorectal fascia involvement.
18 min
Where do we stand? Restaging
To outline the key criteria for high-quality MR imaging and recognise common pitfalls in image interpretation following neoadjuvant therapy.
To explore the role of MRI in assessing rectal cancer response, focusing on its influence on curative surgical planning and patient selection for organ preservation strategies.
To identify MR imaging features indicative of a clinical complete response.
18 min
Where do we go? Functional imaging techniques and DWI
To understand how DWI and other functional imaging may guide decision-making in the clinical management of rectal cancer.
To know emerging trends and future developments in functional imaging, including MRI and DWI technology advances.
To be familiar with the key limitations and challenges of these techniques.
18 min
Where do we go? Use of radiomics and AI
To understand the principles of radiomics and artificial intelligence (AI) in the context of rectal cancer imaging, including the workflow from image acquisition to data extraction and model development.
To evaluate the current and emerging applications of radiomics and AI in rectal cancer for diagnosis, staging, treatment response assessment, and outcome prediction.
To identify the main challenges and future directions for the clinical integration of radiomics and AI, including validation strategies, regulatory considerations, and multidisciplinary collaboration.
15 min
Panel discussion: Enhanced structured reporting or not?